Journal of the American College of Cardiology最新文献

{"title":"From the Hazards of Death to the Hazards of Indication Creep for TAVR.","authors":"Fabio Barili, Nabil Dib, Rita F Redberg, William E Boden, Sanjay Kaul, Alessandro Parolari, Amedeo Anselmi","doi":"10.1016/j.jacc.2025.06.026","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.06.026","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"86 8","pages":"e75-e76"},"PeriodicalIF":22.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Fixed vs Age-Adjusted NT-proBNP Cutoffs to Define Pre-Heart Failure.","authors":"Anping Cai, Lin Liu, Yinqing Feng, Liwen Li, Biykem Bozkurt, James L Januzzi, Carolyn S P Lam, Gregg C Fonarow, Ambarish Pandey, Lin Yee Chen, Yunjiu Cheng, Antoni Bayes-Genis","doi":"10.1016/j.jacc.2025.06.041","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.06.041","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"86 8","pages":"625-629"},"PeriodicalIF":22.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computed Tomography Angiography or Standard Care After Left Main PCI?","authors":"Fabrizio D'Ascenzo, Enrico Cerrato, Ovidio De Filippo, Luca Gaido, Alfonso Franzè, Mario Iannaccone, Wojciech Wańha, Andrea Santarelli, Vincenzo Guiducci, Umberto Barbero, Carlos Fernandez Pereira, Marco Gatti, Matteo Tebaldi, Massimo Giammaria, Giacomo Boccuzzi, Wojciech Wojakowski, Gianluca di Pietro, Roberto Placido, Sebastiano Gili, Alessandro Depaoli, Giuseppe Biondi Zoccai, Francesco Tomassini, Francesco Bruno, Daniela Zugna, Riccardo Faletti, Simone Biscaglia, Serena Caglioni, Ferdinando Varbella, Gaetano Maria de Ferrari, Gianluca Campo","doi":"10.1016/j.jacc.2025.07.060","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.07.060","url":null,"abstract":"<p><strong>Background: </strong>The clinical benefit of routine coronary computed tomography angiography (CCTA) after percutaneous coronary intervention (PCI) for unprotected left main (LM) disease is uncertain.</p><p><strong>Objectives: </strong>The authors evaluated whether CCTA-guided follow-up improves clinical outcomes vs symptoms- or ischemia-driven care after LM PCI.</p><p><strong>Methods: </strong>PULSE was a prospective, multicenter, open-label randomized trial. A total of 606 patients treated with second-generation drug-eluting stents were enrolled (October 2019 to September 2024) and randomized 1:1 to CCTA at 6 months (experimental) or standard care (control). The primary endpoint was a composite of all-cause death, spontaneous myocardial infarction (MI), unstable angina, or definite or probable stent thrombosis at 18 months. Secondary endpoints included target-lesion revascularization (TLR) and each primary endpoint component.</p><p><strong>Results: </strong>CCTA was completed in 272/303 experimental patients (89.8%) after a median of 200 days (IQR: 181-270 days). The primary endpoint occurred in 36/303 experimental patients vs 38/303 control patients (11.9% vs 12.5%; HR: 0.97; 95% CI: 0.76-1.23; P = 0.80). Compared with the control arm, the CCTA arm showed a reduced risk of spontaneous MI (0.9% vs 4.9%; HR: 0.26; 95% CI: 0.07-0.91; P = 0.004) and an increased risk of imaging-triggered TLR (4.9% vs 0.3%; HR: 7.7; 95% CI: 1.70-33.7; P = 0.001), whereas clinically driven TLR rates were similar (5.3% vs 7.2%; HR: 0.74; 95% CI: 0.38-1.41; P = 0.32).</p><p><strong>Conclusions: </strong>Routine CCTA after LM PCI did not reduce the composite primary endpoint, but was associated with fewer spontaneous MIs and more imaging-triggered revascularizations. Future trials to clarify its value in complex anatomic subsets appear to be warranted. (Angiographic Control vs Ischemia-Driven Management of Patients Treated With PCI on Left Main With Drug-Eluting Stents [PULSE; NCT04144881]).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mounting Evidence for Conduction System Pacing in Atrioventricular Block Ushers in a New Era.","authors":"Ratika Parkash, Kenneth A Ellenbogen","doi":"10.1016/j.jacc.2025.06.040","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.06.040","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"86 8","pages":"574-576"},"PeriodicalIF":22.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial.","authors":"Milind Y Desai, Iacopo Olivotto, Theodore Abraham, Steven E Nissen, Pablo Garcia-Pavia, Renato D Lopes, Perry M Elliott, Fabio Fernandes, Edileide de Barros Correia, Roberto Barriales-Villa, Esther Zorio, Michael Arad, Sung-Hee Shin, Nicolas Verheyen, Benjamin Meder, Olga Azevedo, Hiroaki Kitaoka, Kathy Wolski, Qiuqing Wang, Bharat Suryawanshi, Zhaoqing Wang, Victoria Florea, Ron Aronson, Anjali T Owens","doi":"10.1016/j.jacc.2025.08.017","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.08.017","url":null,"abstract":"<p><strong>Background: </strong>No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395) trial, the largest to date in patients with hypertrophic cardiomyopathy (HCM), evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status).</p><p><strong>Objectives: </strong>The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I [cTnI]) with clinical, exercise, and echocardiographic characteristics; and 2) comparing changes in these biomarkers from baseline to week 48 between mavacamten and placebo groups.</p><p><strong>Methods: </strong>Symptomatic nHCM patients were randomized to placebo or mavacamten (starting at 5 mg/d, with titration ranging from 1 to 15 mg, based on left ventricular [LV] ejection fraction). Along with clinical and echocardiographic parameters, NT-proBNP and hs-cTnI were measured for changes from baseline to week 48.</p><p><strong>Results: </strong>Among 580 randomized patients (mean age 56 ± 15 years, 266 [45.9%] women), baseline biomarkers were elevated with median NT-proBNP 917.5 ng/L (IQR: 463-1,725 ng/L) and hs-cTnI of 29.1 ng/L (IQR: 14.4-91.7 ng/L). On multivariable analysis, female sex, body mass index, NYHA functional class, maximal LV wall thickness, left atrial volume index, and E/e' were associated with higher baseline NT-proBNP. Only younger age and LV mass index were associated with higher baseline hs-cTnI level. At week 48, the mavacamten group had a 58% reduction in NT-proBNP (geometric mean ratio: 0.42; 95% CI: 0.37-0.47; P < 0.001) and a 51% reduction in hs-cTnI (geometric mean ratio: 0.49; 95% CI: 0.45-0.53; P < 0.001). No significant change in either biomarker was seen in the placebo group. These reductions occurred early and were maintained through week 48.</p><p><strong>Conclusions: </strong>Treatment with mavacamten for 48 weeks in nHCM patients was associated with marked biomarker improvements compared with placebo. Whether these changes translate into longer-term adaptive remodeling and improvements in patient-reported health status, exercise capacity, and outcomes remain to be ascertained. (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.","authors":"Milind Y Desai, Yuichiro Okushi, Shada Jadam, Iacopo Olivotto, Anjali Owens, Steven E Nissen, Zoran B Popovic, Pablo Garcia-Pavia, Renato D Lopes, Perry M Elliott, Fabio Fernandes, Jeffrey B Geske, Lars Maier, Kathy Wolski, Qiuqing Wang, Wael Jaber, Zhiqun Gong, Victoria Florea, Matthew Fronheiser, Arlene Leva, Ron Aronson, Theodore Abraham","doi":"10.1016/j.jacc.2025.08.019","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.08.019","url":null,"abstract":"<p><strong>Background: </strong>Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to date in HCM patients, evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status).</p><p><strong>Objectives: </strong>This exploratory analysis of the phase 3, randomized, placebo-controlled trial evaluated echocardiographic changes in nHCM patients from baseline to week 48.</p><p><strong>Methods: </strong>Symptomatic nHCM patients were randomized to placebo or mavacamten (5 mg/d, titrated between 1 and 15 mg based on left ventricular ejection fraction [LVEF]). Echocardiographic assessments of LV systolic/diastolic function and left atrial (LA) function were performed at baseline and week 48.</p><p><strong>Results: </strong>Among 580 randomized patients (mean age 56 ± 15 years, 45.9% women), baseline measures included LVEF (65.8 ± 4%), maximal LV wall thickness (20.8 ± 4 mm), LV mass index (122.3 ± 31 g/m²), average E/e' (13.3 ± 6), and LV-global longitudinal strain (-13.2 ± 4%). LA parameters included volume index (43.5 ± 16 mL/m²), reservoir strain (19.1 ± 9%), and conduit strain (-11.6 ± 6%). At week 48, there was significant placebo-corrected treatment difference with patients on mavacamten demonstrating significant reduction in maximal LV wall thickness (-2.1 mm [95% CI: -2.5 to -1.7 mm]), LV mass index (-3.8 g/m² [95% CI: -7.1 to -0.5 g/m²]), and E/e' (-1.3 [95% CI: -2.0 to -0.7]), with a -5.3% [95% CI: -5.9% to -4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF <50% occurred in 62 patients (21.5%) in the mavacamten arm vs 5 (1.7%) in the placebo arm and recovered following drug interruption. Patients in the mavacamten group maintaining LVEF ≥50% throughout the study (n = 212) demonstrated an improvement in LV-global longitudinal strain at week 48 (-0.4% [95% CI: -0.8% to -0.05%]; P < 0.05). LA functional parameters including contractile (-1.1% [95% CI: -1.8% to -0.4%]) and conduit (-1.4% [95% CI: -0.6% to -2.3%]) strain also improved significantly at week 48 (P < 0.05), whereas LA volume was significantly reduced in patients without atrial fibrillation (-2.6 mL/m² [95% CI: -4.7 to -1.11 mL/m²]; P = 0.009).</p><p><strong>Conclusions: </strong>Symptomatic nHCM patients treated with mavacamten demonstrated directional improvements in markers of LV diastolic and LA function, modest regression in LV hypertrophy-related parameters, but 1 in 5 demonstrated an LVEF <50%, which reversed following therapy interruption.</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.","authors":"John W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, Brian L Claggett, Inder S Anand, Akshay S Desai, Pardeep S Jhund, Carolyn S P Lam, Marc A Pfeffer, Bertram Pitt, Faiez Zannad, Michael R Zile, Milton Packer, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan","doi":"10.1016/j.jacc.2025.08.012","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.08.012","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) and is associated with increased risk of disability and death.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The purpose of this study is to explore the association between different adiposity-related anthropometrics and clinical outcomes in this population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this participant-level pooled analysis of 5 international randomized trials that enrolled adults with HFmrEF/HFpEF, the association between adiposity-related anthropometrics (body mass index [BMI], waist circumference [WC], and waist-to-height ratio [WHtR]) and heart failure (HF) and mortality outcomes was evaluated, overall and by age and sex. Independent and combined associations between BMI and/or WHtR and outcomes were also assessed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;At baseline, BMI was available in 21,479 participants, and WC and WHtR were available in 7,827. Overall, 46% had BMI ≥30 kg/m&lt;sup&gt;2&lt;/sup&gt; and 95% had elevated WC or WHtR. Among those with BMI &lt;30 kg/m&lt;sup&gt;2&lt;/sup&gt;, 89% had excess abdominal adiposity, especially older and female participants. Sex (P&lt;sub&gt;interaction&lt;/sub&gt; = 0.003) and race (P&lt;sub&gt;interaction&lt;/sub&gt; = 0.046) modified the association between BMI and WHtR, such that women vs men had higher WHtR at higher BMI, and Asian and Black participants had higher WHtR at lower BMI. Although BMI exhibited complex J- and U-shaped associations with clinical outcomes, higher WHtR was linearly associated with increased risk of HF and mortality events. Younger participants exhibited the steepest associations between BMI or WHtR and cardiovascular death or HF hospitalization (P&lt;sub&gt;interaction&lt;/sub&gt; &lt;0.001 for both). Independent of BMI, higher WHtR was associated with adverse outcomes. Independent of WHtR, higher BMI was associated with HF hospitalization. Participants with elevated BMI and WHtR experienced higher rates of cardiovascular death or HF hospitalization vs those with elevated BMI or WHtR alone.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;These data from 5 large-scale HFmrEF/HFpEF clinical trials further question the utility of BMI as the sole measure to define obesity. WC or WHtR assessment identifies a substantial number of individuals with abdominal obesity despite BMI &lt;30 kg/m&lt;sup&gt;2&lt;/sup&gt;, and may enhance risk stratification beyond BMI alone in HFmrEF/HFpEF. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213; Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711; Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve] (NCT00095238); Candesa","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twice-A-Day CLOpidogrel vs Ticagrelor to Reduce Short-Term MACE after Primary PCI: The TADCLOT Trial.","authors":"Abdul Hakeem, Jehangir Ali Shah, Rajesh Kumar, Asim Ali, Ahsan Ali Lakho, Hamayal Zeeshan, Muhammad Inam Uddin, Kamran Khan, Bashir Solangi, Mukesh Kumar, Mahesh Kumar, Romana Awan, Haroon Ishaq, Faiza Farooq, Ejaz Ul Haq, Abdul Hameed, Waheed A Lehri, Shakir Zada, Asif Ali, Ahsan Raza, Sobia Masood, Ahmadullah Humza, Musa Karim","doi":"10.1016/j.jacc.2025.08.041","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.08.041","url":null,"abstract":"<p><strong>Background: </strong>The first month post-primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is the highest risk period for major adverse cardiovascular events (MACE), including stent thrombosis. Ticagrelor and double dose clopidogrel are effective antiplatelet therapies, but no head-to-head comparison exists in this setting.</p><p><strong>Objectives: </strong>We sought to evaluate the efficacy of ticagrelor over twice daily clopidogrel in reducing MACE events within the first one month post primary PCI.</p><p><strong>Methods: </strong>TADCLOT, a double-blind, randomized superiority trial at the National Institute of Cardiovascular Diseases, Karachi, Pakistan (February 19, 2024-January 30, 2025), randomized 2,201 patients with STEMI within 24 hours of primary PCI 1:1 to ticagrelor (180 mg loading dose, 90 mg BID) or BID clopidogrel (600 mg loading dose, 75 mg BID) for 1 month. The primary endpoint was MACE (death, myocardial infarction, stent thrombosis, stroke, or target lesion revascularization) at 1 month, analyzed by intention-to-treat. Secondary endpoints included individual MACE components and clinically significant bleeding (BARC types 2, 3, or 5).</p><p><strong>Results: </strong>Among 2,201 randomized patients, MACE occurred in 24 (2.2%) ticagrelor patients vs. 32 (2.9%) in BID clopidogrel patients (HR 0.75; 95% CI, 0.44-1.27; P=0.28; ARD -0.7%; 95% CI, -2.05% to 0.60%). Cardiovascular death or definite stent thrombosis occurred in 21 (1.9%) vs. 27 (2.5%) patients (HR 0.77; 95% CI, 0.44-1.37). Clinically significant bleeding (BARC type 2, 3, or 5) occurred in 6 patients (0.5%) with ticagrelor versus 4 (0.4%) with clopidogrel (HR 1.50, 95% CI 0.42-5.31). Major bleeding (BARC 3 or 5) was infrequent and similar between the groups: 3 patients (0.3%) in the ticagrelor arm and 2 (0.2%) in the clopidogrel arm (HR 1.50, 95% CI 0.25-8.97). At both 7 (HR 0.15, 95% CI 0.04-0.5; p=0.002) and 14 days (HR 0.46, 95% CI 0.23-0.91; p=0.02), MACE was significantly lower with ticagrelor compared with BID clopidogrel, although these differences were no longer statistically significant at 30 days.</p><p><strong>Conclusions: </strong>Ticagrelor was not superior to BID clopidogrel in reducing MACE at one month after primary PCI, and bleeding rates were similar. However, event rates were lower than anticipated and ticagrelor significantly reduced MACE within the first 2 weeks compared with BID clopidogrel. (ClinicalTrials.gov, NCT06318481).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting the ODYSSEY-HCM Secondary Analyses-Biological Signals, Clinical Silence.","authors":"Harlan M Krumholz, Michelle M Kittleson","doi":"10.1016/j.jacc.2025.08.020","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.08.020","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ideas Worth Testing: The Adipokine Hypothesis.","authors":"Harlan M Krumholz","doi":"10.1016/j.jacc.2025.08.004","DOIUrl":"https://doi.org/10.1016/j.jacc.2025.08.004","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}